Organon and Shanghai Genomics collaborate on new research project
Advertisement
Organon, the human healthcare business of Akzo Nobel, and Shanghai Genomics Inc announced an agreement to collaborate on a new research project. The collaboration, which will involve biological development work aimed at progressing Organon's program for the identification of more selective steroid hormone receptor modulators, will initially last for a period of two years.
Shanghai Genomics, which in 2005 merged with GNI Ltd., the Asia-based global pharmaceutical company, will use its expertise in protein purification and cell-based interaction assays to clarify the clinical relevance of a number of receptor interacting proteins and their use in drug discovery. In particular, the research will focus upon the areas of rheumatoid arthritis, atherosclerosis and oncology.